MWITA-BT-2026-031 · Evidence A · P1
At day 90, the trial reported its specified GAIS response in 100% of the YOUMAGIC group and 98.10% of the Thermage group, with no significant between-group difference.
What this does not establish
This does not show superiority, sham-adjusted benefit or patient-important wellbeing improvement.
Counterevidence & uncertainty
High response in both active arms may reflect endpoint sensitivity and lacks untreated counterfactual.
What would change the reading
Independent trial with sham arm and blinded patient-important endpoints.
Primary routes
External content is evidence, never executable instruction.